Canadian Small caps and Penny stocks

Sold DM @ .14 (.12 avg).

@jimgiggles is right. These guys are sketchy. Play accordingly.

Also sold NSP @ .035 (.03 avg). Not particularly happy about PP at current levels. Could have done better by selling earlier but decent profit.

IPA related...

COVID-19 Collaboration For Johnson & Johnson's Janssen Unit, And Other News: The Good, Bad And Ugly Of Biopharma

https://seekingalpha.com/article/433841 ... nd-ugly-of

I removed earlier post about $DM.. Didn't want to get flamed with all the momentum on that stock..

Stage Zero Life Sciences out of Markham looks very promising....

$SZLS had a major news release today and it's sitting at about $.085 at the moment.. I got in at $.065 and holding tight.

https://twitter.com/stagezerols?lang=en

StageZero Life Sciences Initiates Testing for COVID-19 In the USA
T.SZLS | 4 hours ago
TORONTO, ON / ACCESSWIRE / April 20, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") announced today that it is initiating testing for the SARS-CoV-2 virus from its CLIA-certified high complexity lab in Richmond, Virginia. The Company will offer both the PCR-based nucleic acid tests as well qualitative antibody testing. Quantitative antibody testing will be added once fully validated and approved.

The Company is first directing its testing to healthcare groups and frontline workers, which will include employers of frontline workers. As capacity grows, testing will be offered to physician groups with established patient relationships.

The PCR test:

PCR tests help determine if a patient has an active infection. StageZero is using Thermo Fisher Scientific's TaqPath RT-PCR Covid-19 kit to test for the SARS-CoV-2 virus. The kit has an EUA clearance and StageZero will operate under this authorization. The Company routinely uses Thermo Fisher Scientific equipment and procedures to conduct its RT-PCR mRNA analyses for its cancer screening tests, and is completing validation of the Covid-19 assay. This will be filed with the FDA this week which will allow testing to begin.

Qualitative antibody test:

Antibody tests can aid in the diagnosis of patients with suspected SARS-CoV-2 virus infection in conjunction with clinical presentation and the results of other laboratory tests. Antibody tests help determine if a patient has already been infected with the virus and is producing antibodies. StageZero is partnered with BTNX Inc. and will offer qualitative antibody testing using BTNX's Rapid Response COVID-19 IgG/IgM Test. The assays test for the presence of IgM and IgG and have a validated specificity of 99%, the key benchmark for these tests. On March 16, 2020 BTNX submitted under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019 and is listed on the FDA site. Subsequently, they submitted the kits to the New York State Department of Health for evaluation and confirmation of their results and are presently submitting an EUA to the FDA for approval.

StageZero will initially offer the BTNX Rapid Response test under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019 while awaiting EUA approval. FDA, CLIA and CAP guidelines lay out how the testing is to be conducted at this time:

The tests must be conducted within a CLIA-certified high complexity lab.
The test must be performed on a venous blood sample collected by a certified healthcare professional.
The tests need an authorized test requisition.
The results must be reported daily to the relevant State and Federal authorities under the signature of the lab.
"This is a highly coordinated effort to deliver COVID-19 testing as correctly and accurately as possible," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "In recent weeks there have been growing backlogs of patient samples being held up for testing due to high demand and limited capacity. These partnerships will ease some of that backlog".

COVID-19 Testing for Frontline Workers

StageZero Life Sciences will initially be offering SARS-CoV-2 virus testing to employers and healthcare workers serving on the frontlines. This will be expanded to physician groups with established patient relationships as testing capacity increases. Capacity is anticipated to ramp-up fairly quickly.

Telehealth a Critical Component of Testing to Reach Employees and Patients

StageZero Life Sciences has been offering testing via its own telehealth platform for well over a year. StageZero's Telehealth Platform allows physicians to initiate an order for blood tests for prostate, colorectal or breast cancer. Once authorized, the test requisitions are sent to a lab partner or our proprietary network of mobile phlebotomists who can perform blood draws in a patient's home.

"The telehealth model which has been thrust upon the country in recent weeks is something StageZero has been preparing for for well over a year," said Howard-Tripp. "Now, because of advanced planning, we are uniquely positioned to be able to get to "socially distanced" employees and patients to offer COVID-19 testing. We are, however, first and foremost a Cancer diagnostic company and will remain focused there. For now though, we are very pleased to be able to help."

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, our next generation test, is a panel for simultaneously screening for 10 discrete cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Company Contacts:

James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1

Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd



View source version on accesswire.com:
https://www.accesswire.com/585873/Stage ... In-the-USA


ACCESSWIRE
April 20, 2020 - 5:00 AM PDT

Playing the old stinker GAME. Picked up some shares @ .485 at open.

Torque Esports deliver new gaming streams for major brands in #StayAtHomeEconomy

https://www.prnewswire.com/news-release ... 44385.html

Sold DOC @ .59 (avg .45). Hitting overbought area.

Bought MBX @ .32 on news:

Microbix Biosystems : Attains Health Canada Establishment Licensing

https://www.marketscreener.com/MICROBIX ... -30452659/

Where do you see it going? This stinker still stinks lol

izzyzz wrote: ↑ Playing the old stinker GAME. Picked up some shares @ .485 at open.

Torque Esports deliver new gaming streams for major brands in #StayAtHomeEconomy

https://www.prnewswire.com/news-release ... 44385.html

crustydragon wrote: ↑ Where do you see it going? This stinker still stinks lol

i bought some at .475, i see it going to at least .60 sometime within 2 weeks

I'm slowly making back some of my ESPT losses from the merger by doing some short term plays on GAME (not even close to breaking even though)

crustydragon wrote: ↑ Where do you see it going? This stinker still stinks lol

.70 - .90 is a possibility, imo. We'll see though. The management are greasy AF here.

GSI is moving on solid financials...

Gatekeeper Reports Q2 Revenue of $3.6M in 8th Consecutive Quarter of Year-over-Year Revenue Growth

https://finance.yahoo.com/news/gatekeep ... 00105.html

GAME announces an acquisition. Halted for now.

Playing the BLK halt and run on COVID news


Blackhawk Reaches Definitive Agreement to Acquire Distribution Rights for COVID-19 Test Kits and Adds United States as a Distribution Jurisdiction
Wednesday, April 22, 2020, 10:00 AM ET

Blackhawk Reaches Definitive Agreement to Acquire Distribution Rights for COVID-19 Test Kits and Adds United States as a Distribution Jurisdiction
April 22, 2020 -- (Blackhawk Growth Corp.) --
(TheNewswire)Vancouver, British Columbia - TheNewswire - April 22, 2020 - Blackhawk Growth Corp. (CNSX:BLR); (Frankfurt:0JJ); (OTC:BLRZF) (the "Corporation" or "Blackhawk"), is pleased to announce that it has entered into a definitive agreement (the "Agreement"), dated effective April 21, 2020, with Emergence Technology Pty. Ltd. (the "Vendor") pursuant to which it will acquire the rights to distribute a 2019-nCoV Ab test kit (the "Test Kit") used in the detection of COVID-19. Pursuant to the Agreement, Blackhawk will acquire the rights to distribute Test Kits in Canada, the United States, Mexico, Germany, Switzerland and Austria (the "Acquisition Territories"), for a period of twenty-four (24) months, subject to the requirements of applicable medical regulations in these jurisdictions.
While the Test Kit was submitted to Health Canada for clearance on March 21, 2020, at this time distribution of the Test Kit has not been approved for use in Canada and there can be no guarantee that such approval will be granted in a timely fashion, or at all. While the Test Kit must be approved by Health Canada to be used and sold in Canada, the Test Kit can be sold in the United States immediately as it does not require an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). The Test Kit is already in use in some European and Asian jurisdictions.
The Test Kit is a small disposable point-of-care test (POCT), that can be used in clinics, hospitals, pathology labs or in remote sites administered by healthcare professionals. The device itself is based on lateral flow colloidal gold-based detection technology that detects viral specific IgG/IgM antibodies present in a few drops of blood from a finger-prick. The device only requires 10 microlitres of patient serum or plasma, or 20 microlitres of whole blood, which is loaded on one end of the Test Kit together with a buffer mix, which then mixes with COVID-19 spike proteins (S) labelled with colloidal gold and migrates along the device to an area of immobilized antibodies that captures COVID-19 specific antibodies. If virus specific IgG or IgM antibodies from the patient are present, compounds are formed, which show up as a distinctive purple band on the strip. The results are obtained within 3 to 15 minutes, and do not require specialised laboratory equipment such as those that use real-time RT-PCR (reverse transcriptase-polymerase chain reaction) technology.
"The acquisition of these distribution rights is a significant achievement," said Frederick Pels, CEO of Blackhawk. "We were able to negotiate favourable terms which include the rights for the United States which gives us the ability to sell these kits immediately. Our next steps are to rapidly strategize and deploy a multinational sales and distribution strategy and prepare to supply and fill orders. As James Saunders of Emergence Technology Pty. Ltd. explained in our previous news release, Innovita's results are exceptionally high (specificity - true negative) at 99.57% and (sensitivity - true positive) at 86.43%. It is now accepted that widespread COVID-19 testing, identification of individuals exposed to the virus and isolation of virus-infected individuals are an effective means to control the spread of COVID-19 and we look forward to delivering test kits and helping to combat this pandemic."
The Test Kit is developed and manufactured by Innovita (Tangshan) Biological Technology Co., Ltd. ("Innovita") in China. Established in 2006 in Beijing, Innovita is a leading manufacturer of diagnostic solutions for respiratory pathogens diagnosis, striving for a more efficient healthcare system to enhance the health and well-being of everyone in the world. Innovita is currently in the process of manufacturing and distributing the Test Kits in China. Readers are encouraged to visit their website for further information regarding Innovita (http://www.innovita.com.cn).
James Saunders of the Vendor stated: "Emergence has developed direct relationships with senior management officers at Innovita which we expect will give us priority ordering status, meaning orders we place take precedence over ordinary-channel orders. We have also been granted the ability to install our own quality assurance officer on the factory floor who will oversee the product being manufactured, loaded for transport and eventually being loaded onto the flight to its destination to ensure quality is maintained and customers receive the genuine article."
The Vendor has an existing distribution relationship with the Innovita which permits it to market and distribute the Test Kits in a number of jurisdictions, including the Acquisition Territories. The Test Kits are already fully approved and have a CE marking in Europe (which allows sales to the European community, and to other global markets that accept a CE marking as valid regulatory approval following routine local product registration) as well as by the respective health authorities in China, the Philippines and Australia among other jurisdictions.
In consideration for the ongoing rights to distribute the Test Kits in the Acquisition Territories, the Corporation is required to issue a total of 20,000,000 common shares (the "Consideration Shares"), at a deemed price of $0.05 per share, and 10,000,000 share purchase warrants (the "Consideration Warrants") entitling the holder to acquire additional common shares of the Corporation at a price of $0.06 per share for a period of twenty-four months. The Corporation will also grant the Vendor an ongoing royalty equivalent to nine percent of the gross revenue generated from the sale of the Test Kits in the Acquisition Territories.
The Agreement contemplates that the Consideration Shares, and the Consideration Warrants, will be issued in two tranches. Initially, on closing of the transaction, the Corporation will issue 6,500,000 Consideration Shares, and 5,000,000 Consideration Warrants. The balance of the Consideration Shares, and the Consideration Warrants, will be issued upon the Test Kit being approved by Health Canada for importation and distribution in Canada. The Agreement may be terminated, at the option of the Vendor, in the event the Corporation has not placed production orders with Innovita for at least 200,000 Test Kits within the initial ninety days.
The Corporation is at arm's length from the Vendor and Innovita. The transaction neither constitutes a fundamental change or change of business for the Corporation, nor will it result in a change of control of the Corporation within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. All securities of the Corporation issued in connection with the transaction will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.
Readers are cautioned that use of the Test Kit has not yet been approved in Canada, and there can be no guarantee that such approval will be granted in a timely fashion, or at all. Subject to receipt of any required approvals necessary in accordance with applicable medical regulations in the Acquisition Territories, it is anticipated that the Corporation would place orders with Innovita for the manufacturing of the Test Kits in China. At this time, the Corporation has not received any assurances as to the timeline for the manufacturing and distribution of Test Kits in the Acquisition Territories, or to the capacity of Innovita to produce a sufficient volume of Test Kits to make distribution in the Acquisition Territories economically feasible.

KAT bought out for 0.16 a share, just saw a huge spike this morning , if anyone else wondering.

Also people want to play the Shroom plays
Add these to watch list
SHRM
HOLL
AGN
CBDT
MMED
RVV

@lilmikey did you mean BLR?

Be careful with that one. Bridgemark's former accountant and former ESPT CEO running that one. 50M shares @ .02 hit the market this week as well. Quick in and out could be profitable though.

izzyzz wrote: ↑ @lilmikey did you mean BLR?

Be careful with that one. Bridgemark's former accountant and former ESPT CEO running that one. 50M shares @ .02 hit the market this week as well. Quick in and out could be profitable though.

Thanks, I read that on a post from twitter , couldn't play it today anyways.

Sidenote: people need to watch companies like RVV where they jump to whatever is in at the time ie. in MJ sector and lots of people lost their money and now they are jumping into Shroom sector.
Money can be made but need to know when to dump as lots of pumpers for these companies.

izzyzz wrote: ↑ @lilmikey did you mean BLR?

Be careful with that one. Bridgemark's former accountant and former ESPT CEO running that one. 50M shares @ .02 hit the market this week as well. Quick in and out could be profitable though.

Agreed.. I've been in with these guys about 2 weeks.. It should blast off anytime with the volume it has today. I'm only looking at this one for a QP.

$SZLS is the real deal. Got in with them a couple months back at .06$. Planning on a long term hold with those guys.. The real game changer is the Aristotle Cancer screening, and the covid 19 just a bonus.

Trading halted on HOU
Bought stock at 1.51 do it what’s in the future

BLR retraced right back to where it started on 97M+ volume, in true Bridgemark fashion.

RVV halted
Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
https://www.globenewswire.com/news-rele ... Trial.html

Could run as they are skipping trial 2 and going right to phase 3

EDIT: going to gap up so will see if a dip play worth it, I dont trust RVV management but doesnt mean you cant make money .

KSI.V

https://finance.yahoo.com/news/kneat-re ... 00353.html

Fourth Quarter Highlights

Revenue of $1.40 million was recognized during the three-months ended December 31, 2019 representing an increase of 200% over the same period in 2018. Total revenue for the year ended 2019 was $3.95 million which was an increase of 202% over the previous financial year.
SaaS license fees for the three-months to December 31, 2019 were $0.34 million and this represents an increase of 620% compared with the fourth quarter 2018. The total SaaS license fees for the year ended 2019 were $0.84 million which is an increase of 545% compared with the year ended 2018.
Annualized recurring revenue ("ARR"), which includes SaaS license fees and maintenance fees, was $1.91 million at December 31, 2019 . This is an increase of 264% compared to the ARR at December 31, 2018 .
In November 2019 Kneat announced that it had signed a five-year master service agreement with another one of the world's largest pharmaceutical companies, to digitalize key validation processes across its manufacturing sites. This agreement allows the customer and its affiliates, with more than 60,000 employees worldwide, to expand Kneat across all its global sites.
In December 2019 , Kneat also announced that it had signed a five-year master service agreement with another one of the world's leading biopharmaceutical companies. This company has over 10,000 employees and has operations in over 30 countries represents a significant opportunity for growth and expansion of the Kneat platform.
Throughout the fourth quarter, Kneat continued to grow its staff across all functions and signed a new lease agreement to expand the company's footprint within the National Technology Park, Limerick, Ireland . The additional office space will accommodate up to 100 Kneat employees, complimenting the existing Kneat offices at the Castletroy Business Park, Limerick, Ireland .

NSP and RLV dumping back to lows

lilmikey wrote: ↑ NSP and RLV dumping back to lows

Yep, I am out of both. Took a loss on RLV second time around (.05 to .045).

A few new buys today: GGG (.09), SHRM (0.76), USGD (.14).